"uuid:ID","instanceType","description","label","id","name","rationale"
"b449bf11-5b88-4680-8045-e10892e59f3b","StudyDesign","The main design for the study","","StudyDesign_1","Study Design 1","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated."
